IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.

Date publication

août 2019

Journal

The Lancet. Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BENSUSSAN Armand

Tous les auteurs :
Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, Whittaker S, Rotolo F, Ram-Wolff C, Khodadoust MS, Bensussan A, Paturel C, Bonnafous C, Sicard H, Azim HA, Kim YH

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31253572

Résumé

IPH4102 is a first-in-class monoclonal antibody targeting KIR3DL2, a cell surface protein that is expressed in cutaneous T-cell lymphoma, and predominantly in its leukaemic form, Sézary syndrome. We aimed to assess the safety and activity of IPH4102 in cutaneous T-cell lymphoma.

Mots clés

Aged, Antineoplastic Agents, Immunological, administration & dosage, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, drug effects, Female, Humans, Lymphoma, T-Cell, Cutaneous, drug therapy, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Recurrence, Local, drug therapy, Receptors, KIR3DL2, antagonists & inhibitors, Skin Neoplasms, drug therapy

Référence

Lancet Oncol. 2019 08;20(8):1160-1170